As Doctors Mount Pressure On Government, India Bans Diabetes Drug Rosiglitazone In Line With EU Action
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - The Drug Controller General of India has banned use of anti-diabetes agent rosiglitazone following a meeting of an expert committee called by the Ministry of Health and Family Welfare to study the safety issues related to the drug